Background: Skin rash is an adverse event which might be associated with longer survival in patients treated with epidermal growth factor receptor tyrosine kinase inhibitors. The aim of this nonrandomised phase II clinical trial is to prospectively evaluate the relationship between skin rash and overall survival (OS) in advanced/metastatic pancreatic cancer treated with erlotinib plus gemcitabine.
introduction Pancreatic cancer is a major concern because of the lack of effective treatments available and its high mortality, representing the fourth leading cause of cancer-related mortality in the United States [1] and fifth in Europe [2] . Gemcitabine has been considered as the standard first-line treatment based on the benefit showed in symptom control over fluorouracil [3] . Although several chemotherapy combinations have been tested to improve gemcitabine efficacy, most of them have failed to provide significant benefit or have caused unacceptable toxicity. The addition of erlotinib to gemcitabine treatment was the first regimen to demonstrate a statistically significant improvement in survival compared with gemcitabine alone in patients with advanced pancreatic cancer [4] .
Erlotinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that is currently approved in combination with gemcitabine for the treatment of metastatic pancreatic cancer. Since EGFR is known to be frequently overexpressed in pancreatic cancer and is associated with worse outcome and more aggressive disease [5] , EGFR inhibition by erlotinib might be particularly beneficial in the management of this disease. However, EGFR is also expressed in basal epidermal keratinocytes of the epidermis, sebaceous glands and hair follicles, where EGFR inhibition by erlotinib might lead to growth arrest and inflammation causing skin rash [6] .
Associated skin rash is characterised by clusters of pustular lesions that are mainly developed on the face, neck and upper body [7] . Although skin rash is a common adverse event, several clinical trials have also suggested a relationship between the development of rash and longer survival in non-small-cell lung cancer (NSCLC) [8] [9] [10] , head and neck squamous cell carcinoma [11] and ovarian carcinoma [12] . There is little information in this respect on pancreatic cancer. However, the phase III clinical trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) study PA.3 showed that patients taking gemcitabine plus erlotinib had a higher likelihood of achieving disease control and survived significantly longer after developing skin rash, which suggests a possible relationship between rash and increased overall survival (OS) in advanced pancreatic cancer [4] . Moreover, the randomised trial AViTA supported this finding by observing that patients with pancreatic cancer on erlotinib-based therapy experiencing skin rash had better survival than patients without skin rash [13, 14] .
In view of all these findings, the aim of this clinical trial was to prospectively evaluate the relationship between grade ≥2 skin rash and OS in patients with unresectable and/or metastatic adenocarcinoma of the pancreas treated with erlotinib plus gemcitabine.
patients and methods
This multicentre, nonrandomised, open-label, phase II clinical trial was conducted in accordance with the Helsinki Declaration of the World Medical Association, all its amendments and national regulations. The study was approved by the participating institutions' ethic committees and the reference ethic committee (Hospital Clínico San Carlos, Madrid, Spain). All patients provided their written informed consent before study enrollment.
patient population
The study population consisted of adult patients with histological or cytological evidence of unresectable locally advanced (stage III) and/or metastatic (stage IV) adenocarcinoma of the pancreas; Karnofsky performance status (KPS) ≥60% and adequate haematologic, renal and hepatic function. Patients with a history of other primary neoplasia in the last 5 years (except carcinoma in situ of the cervix or adequately treated skin basal cell carcinoma), uncontrolled hypertension, clinically significant cardiovascular disease, prior/current uncontrolled neurologic disorders or central nervous system metastases were excluded from the study. Patients with adjuvant chemotherapy in the last 6 months or prior systemic treatment of metastatic pancreatic cancer were also excluded. Gemcitabine treatment was allowed as previous adjuvant chemotherapy, while EGFR tyrosine kinase inhibitor treatment was not.
study treatment
Patients received 100 mg/day of oral erlotinib (Tarceva®; F. Hoffmann-La Roche Ltd, Basel, Switzerland) combined with 1000 mg/m 2 assessments Tumour assessments were carried out every 8-10 weeks (two cycles) until disease progression using Response Evaluation Criteria in Solid Tumors guidelines [15] . OS was calculated from the date of enrollment to death. Progression-free survival (PFS) was measured from the date of enrollment to progression or death. Toxicity was assessed at every visit using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0 [16] . Rash was also graded according to the NCI-CTC version 3.0. Rash was managed according to investigator's criteria but directions from the HER1/EGFR-Inhibitor Rash Management Forum were recommended [17] .
statistical considerations
The primary study end point was OS in patients with grade ≥2 rash and grade <2 rash. Sample size calculation was based on OS, assuming a median OS <5.75 months in patients with grade <2 rash to detect an increase of ≥50% in the OS of patients with grade ≥2 rash (median OS ≥ 10.5 months). Based on a power of 80% and a type I error rate of 5%, a total population of 151 patients was required. A ratio 2 : 1 was estimated, since the incidence of grade ≥2 rash was ∼33% [18] . Secondary study end points included PFS, overall response rate, clinical benefit, safety and factors associated with rash in patients with grade ≥2 rash and grade <2 rash.
OS and PFS were estimated using the Kaplan-Meier method. Log-rank or Breslow tests were used to compare OS and PFS between grade ≥2 and grade <2 rash. A subanalysis of the OS and PFS in patients with grade <2 rash (without rash and grade 1 rash) was also carried out using the Kaplan-Meier method and log-rank test. Cox regression analysis was used to evaluate the effect of independent variables (gender, age, KPS, disease stage, rash, cumulative dose of erlotinib and disease control) on OS. Response rates between patients with grade ≥2 and grade <2 rash were compared using the chi-square test or Fisher's exact test. Differences in the time to the first rash and to the maximum grade of rash between patients with grade ≥2 and grade <2 rash were calculated using the Student's t-test. A normal approximation for the proportion hypothesis test was used to compare toxic effects between patients with grade ≥2 and grade <2 rash. A significance level of 0.05 was used for statistical testing. The statistical analysis was carried out with the Statistical Package for the Social Sciences version 17.0 (SPSS Inc., Chicago, IL).
results

patient characteristics
Between May 2007 and December 2008, a total of 156 patients were enrolled into the study. One patient was not eligible for treatment because of the lack of adequate hepatic function. Therefore, 155 patients were assessable for toxicity as they received at least one dose of study treatment. Of those patients, two were ineligible for efficacy analysis as histological/cytological unresectable locally advanced and/or metastatic adenocarcinoma of the pancreas could not be confirmed (one of whom also presented history of other primary neoplasia in the last 5 years). Then, 153 patients were evaluable-for-efficacy analysis in the study: 38 patients (25%) presented grade ≥2 rash and 115 patients (75%) grade <2 rash (grade 1 rash, 44 patients; no rash, 71 patients). All reported rashes were of acneiform type. The baseline characteristics of these patients are shown in Table 1 .
study treatment
The number of treatment cycles received by patients with grade ≥2 rash was significantly higher than patients with grade original articles Annals of Oncology <2 rash [median (range), 7 (4-9) versus 3 (2-5); P < 0.001]. The dose intensity of erlotinib and gemcitabine and the incidence of patients with at least one dose delay or dose reduction did not significantly differ between groups (Table 2) . Only three patients experienced any dose delays or dose reductions due to rash: a dose reduction in one patient with grade 3 rash, two dose delays in one patient with grade 3 rash and another dose delay in one patient with grade 2 rash. Interruptions in dosing due to rash were not needed in any patient.
Twenty patients (53%) with grade ≥2 rash and 68 patients (59%) with grade <2 rash withdrew from the study because of disease progression. Other reasons for withdrawal were adverse events [7 (18%) Likewise, cumulative dose of erlotinib to the first rash did not significantly differ in patients with grade ≥2 rash versus grade <2 rash [mean ± standard deviation (SD), 4034 ± 3052 mg versus 4059 ± 2613 mg] but cumulative dose of erlotinib to the maximum grade of rash was significantly higher in patients with grade ≥2 rash (mean ± SD, 7184 ± 6609 mg versus 4059 ± 2613 mg; P = 0.009).
efficacy
At database closure (May 2010), the median follow-up was 6 (3-11) months [grade ≥ 2 rash, 10 (6-15) months; grade <2 rash, 4 (3-9) months]. One-year survival was 25% and median OS was 6 (5-7) months. Patients with grade ≥2 rash showed significantly larger 1-year survival than patients with grade <2 rash (42% versus 19%; P < 0.005) and longer OS [median, 11 versus 5 months; hazard ratio (HR), 0.392; 95% confidence interval (CI) 0.251-0.613; P < 0.001; Figure 1A] . Moreover, patients without rash had significantly shorter OS than patients with grade 1 rash (median, 3 versus 7 months; HR, 0.472; 95% CI 0.313-0.711; P < 0.001; Figure 1B ) and grade ≥2 rash (median, 3 versus 11 months; HR, 0.271; 95% CI 0.168-0.439; P < 0.001; Figure 1B) . A multivariate Cox regression analysis showed that higher cumulative dose of erlotinib (HR, 0.99992; 95% CI 0.99989-0.99995; P < 0.001), disease control rate (HR, 1.780; 95% CI 1.064-2.977; P < 0.05) and KPS (HR, 0.967; 95% CI 0.950-0.984; P < 0.001) were significantly associated with longer OS. Moreover, grade ≥2 rash was significantly associated with longer OS (HR, 0.426; 95% CI 0.243-0.744; P < 0.005) in patients with KPS >80%, in whom OS was significantly longer in patients with grade ≥2 rash than those with rash <2 (median, 11 versus 6 months; P < 0.005). In patients with KPS ≤80%, although the Cox regression analysis found a nonsignificant tendency to association between grade ≥2 and OS (P = 0.069), the Kaplan-Meier method showed statistically significant longer OS in patients with grade ≥2 rash Missing data n = 17 for grade ≥2 rash and n = 51 for grade <2 rash. b Missing data n = 1 for grade ≥2 rash and n = 3 for grade <2 rash.
*P < 0.005. Patients with at least 1 dose delay, n (%)
(58) 50 (44)
Patients with at least 1 dose reduction, n (%) 12 (32) 20 (17) than those with grade <2 rash, especially during the first year (median, 10 versus 4 months; P < 0.05).
Patients showed a median PFS of 3 (3-4) months, which was significantly longer in patients with grade ≥2 rash than patients with grade <2 rash (median, 6 versus 3 months; HR, 0.455; 95% CI 0.305-0.678; P < 0.001; Figure 2A) . A subanalysis of the PFS using data from the group of grade <2 rash showed that patients without rash had significantly shorter PFS than patients with grade 1 rash (median, 2 versus 4 months; HR, 0.572; 95% CI 0.387-0.845; P = 0.005; Figure 2B ) and patients with grade ≥2 rash (median, 2 versus 6 months; HR, 0.353; 95% CI 0.230-0.541; P < 0.001; Figure 2B ).
Patients with grade ≥2 rash showed significantly higher rates of partial response (18% versus 5%; P = 0.011) and stable disease (63% versus 36%; P = 0.0027), as well as lower rates of disease progression (11% versus 53%; P < 0.001) than patients with grade <2 rash. Significantly higher rates of overall response (complete response + partial response; 21% versus 7%; P < 0.05) and disease control (complete response + partial response + stable disease; 84% versus 43%; P < 0.05) were observed in patients with grade ≥2 rash than those with <2 rash. KPS was maintained without statistically significant differences either between groups or in their evolution within each group during the first four cycles of treatment. Despite the lack of significant differences between patients with grade ≥2 and grade <2 rash in body weight, its evolution within each group was different along the first three cycles of treatment. While patients with grade ≥2 rash maintained their body weight, it decreased in those with grade <2 rash (P < 0.05).
safety
The number of patients with erlotinib-related adverse events and noncutaneous adverse events did not statistically differ between patients with grade ≥2 and grade <2 rash. The most common noncutaneous erlotinib-related adverse events included asthenia and diarrhoea (Table 3 ). There were no statistically significant differences in the frequency of erlotinibrelated grade 3/4 adverse events experienced by patients with grade ≥2 rash and those with grade <2 rash. The most common erlotinib-related grade 3/4 adverse events were rash and neutropenia in patients with grade ≥2 rash and asthenia and neutropenia in those with grade <2 rash ( Table 3 ). The frequency of elevated liver enzymes was low in patients with grade ≥2 and grade <2 rash either considering all grades of severity (8% versus 2%) or just grade 3/4 (5% versus 1%). 
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Likewise, hypomagnesaemia was reported at a low frequency and only as grade 1 in both groups (2.6% versus 2.6%). Only one death was attributed to an adverse event ( pulmonary embolism) possibly related to the study treatment.
discussion
The results of the present study prospectively showed a relationship between development of rash and improved OS, PFS and response to treatment with erlotinib plus gemcitabine. Patients with grade ≥2 rash showed significantly higher rates of partial response and stable disease which led to higher rates of overall response and disease control. These results matched the last data analyses of the NCIC CTG study PA.3, in which disease control increased with the occurrence and severity of rash during erlotinib plus gemcitabine treatment (no rash, 49%; grade 1, 58%; grade ≥ 2, 74%; P = 0.002) [19] . The disease response rate was also higher in grade ≥2 rash, although this improvement was not statistically significant (no rash, 6%; grade 1, 7%; grade ≥ 2, 15%). However, no statistically significant differences related to rash grade were detected in patients who only received gemcitabine.
The benefit achieved in the present study in terms of PFS and OS by subgroups of patients in relation with rash development is especially relevant. The results show a clear improvement in these variables in terms of any-grade rash occurrence and increase in rash grade. Previous studies that evaluated erlotinib and gemcitabine administered in patients with pancreatic cancer retrospectively suggested the association between rash and better outcome [4, 13, 14, 19] . NCIC CTG study PA.3 showed that patients survived significantly longer after developing skin rash (no rash, 5 months; grade 1, 6 months; grade ≥ 2, 11 months; P < 0.001) [4] . Further analysis showed a strong correlation between grade ≥2 rash and survival (grade ≥ 2, 11 months; no rash, 5 months; HR, 0.47; P < 0.001), as well as between grade ≥2 rash and PFS (grade ≥ 2, 7 months; no rash, 3 months; HR, 0.46; P < 0.001) [19] . However, no correlation was found between either grade 1 rash and OS (grade 1, 6 months; no rash, 5 months; HR, 0.90; P < 0.507) or grade 1 rash and PFS (grade 1, 4 months; no rash, 3 months; HR, 0.94; P = 0.692) [19] . The results obtained in AViTA trial confirmed the association detected in the NCIC CTG study PA.3 between rash and improved outcomes [13, 14] . However, this benefit was observed not only for severe rash but also for all grades of rash in both OS (no rash, 4 months; grade 1, 7 months; grade ≥ 2, 8 months; P < 0.0001) and PFS (no rash, 2 months; grade 1, 4 months; grade ≥ 2, 4 months; P < 0.0001) [13] . Likewise, our study revealed significantly longer OS in patients with grade ≥2 and grade 1 rash in comparison with patients without rash. This longer survival in patients with grade ≥2 and grade 1 rash was also observed in some clinical trials carried out in patients with NSCLC during administration of erlotinib [9] or erlotinib plus gemcitabine [19] . Besides, a pooled analysis of data from patients receiving erlotinib during three phase II trials in NSCLC, ovarian cancer and head and neck squamous cell carcinoma showed longer OS in patients with both grade 1 and grade ≥2 rash than patients without rash [20] .
The reasons why some patients develop rash during treatment with EGFR-targeted agents and the underlying reason for the association between development of rash and response remain unclear. Among patients with pancreatic cancer, skin rash has been reported to be more likely in patients below 65 years [4] and with a good performance status [4, 19] . Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 showed a higher incidence of grade ≥2 rash compared with those with an ECOG performance status of 2 [19] . Moreover, this study supports the association of grade ≥2 rash and OS in patients with good performance status. Additionally, several potential explanations for developing skin rash and its association with better outcomes have been proposed. One explanation is a pharmacological hypothesis, based on drug plasma concentrations and variability in drug absorption or metabolism [21] . Supporting this hypothesis, a phase I doseescalation study in patients with solid malignancies suggested an increasing incidence of cutaneous toxicity as the erlotinib dose increases [22] . A later study showed that erlotinib plasma concentration was significantly associated with development of grade ≥2 rash and that interindividual pharmacokinetic variability might be a dominant determinant of erlotinib skin toxicity in patients with NSCLC, head and neck cancer or ovarian cancer [23] . An alternative explanation for the association between rash and efficacy is based on the genetic variability affecting EGFR expression [21] . Actually, s/L allele length in cytosine-adenosine dinucleotide repeats in the intron 1 of the EGFR was significantly associated with higher risk of toxicity relative to s/s in patients with NSCLC, head and neck cancer or ovarian cancer treated with erlotinib [23] . However, whether EGFR polymorphisms correlate with response to EGFR tyrosine kinase inhibitor therapy in pancreatic cancer is still unknown [21] . Moreover, an analysis of markers in the EGRF pathway during erlotinib treatment found that skin rash was linked to post-treatment mitogen-activated protein kinase activity and negatively associated with pretreatment Akt levels [24] . Therefore, changes in the EGFR signalling pathway also appear to be involved in the variability of developing skin rash, and low skin Akt activity might help to identify patients who are more likely to develop skin rash from erlotinib [24] .
In conclusion, since previous studies assessed rash-efficacy relationship retrospectively, the present manuscript is the first report of a clinical trial that prospectively confirms the relationship between the appearance of any grade of rash and longer OS and PFS in patients with unresectable locally advanced and/or metastatic adenocarcinoma of the pancreas treated with erlotinib plus gemcitabine. Disease control and overall response rates were higher in patients with grade ≥2 rash, whereas the rate of disease progression was lower. Moreover, the combination of erlotinib and gemcitabine was found to be similar and well tolerated in patients with grade <2 rash and those with grade ≥2 rash. Further research needs to be carried out to identify patients who are prone to develop skin rash and to completely clarify the underlying mechanism involved in the improved outcome in patients with skin rash.
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